Recent reports indicate that the U. S. Food and Drug Administration (FDA) is considering ending the emergency use authorization (EUA) for Pfizer's COVID-19 vaccine in children under 5 years old. This comes amid ongoing discussions around the vaccine's approval status for various age groups.
• Pfizer's COVID-19 vaccine for under-5s has been available under EUA since June 2022, but has never received full approval. If the EUA is rescinded, no COVID-19 vaccine would be authorized for healthy children under 5, although off-label use of Moderna’s vaccine could still occur.
• The CDC has informed state and local health departments about this potential change, but the U. S. Department of Health and Human Services has not confirmed it and described any regulatory changes as speculation.
• Vaccination rates among young children remain low, with only 5.6% of those aged 6 months to 5 years vaccinated, and about 15% among 5 to 17-year-olds. The CDC’s guidance has shifted from universal vaccination to a decision-making model involving parents and healthcare providers.
• Critics, including pediatricians, are concerned about the risks posed by mRNA vaccines for young children, citing adverse effects like myocarditis and neurological issues, along with a low risk of severe COVID-19 in this demographic.
• Pfizer is seeking to extend the EUA for its vaccine through the 2025-2026 season while also working toward full approval for the vaccine for children aged 5-11.
• Legal challenges have been raised against pediatric COVID-19 vaccine EUA decisions, but previous challenges have been dismissed.
The possible withdrawal of the EUA for Pfizer’s vaccine in young children reflects a shift in regulatory and public health approaches to COVID-19 vaccination. The ongoing controversy focuses on the balance between vaccine safety, necessity, and public health priorities.
https://www.naturalnews.com/2025-08-15-highly-corrupt-fda-cdc-pretending-plandemic-happening.html
No comments:
Post a Comment